126 results
8-K
EX-4.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy
8-K
EX-4.2
RVPH
Reviva Pharmaceuticals Holdings Inc.
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale
8-K
EX-99.1
mjmz5agd 0b0kw
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
gtkx1x6mk jb60p8xq
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K/A
bwqedj8ivnp4
14 Nov 23
Changes in Registrant's Certifying Accountant
4:15pm
8-K
3t4oi07qoxlr60z9
4 Oct 23
Changes in Registrant's Certifying Accountant
5:02pm
8-K
n12p80 l11pn1
24 Jul 23
Changes in Registrant's Certifying Accountant
4:16pm
424B4
k6380fhivhi989
18 Oct 22
Prospectus supplement with pricing info
7:01am
8-K
EX-99.1
w66ji3j9po
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-4.2
qtkrcxft
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.2
svyfk
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-5.1
ssxi7 d38a
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-4.1
cfcwbfr99t m1omaf5
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm